Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Mesenchymal Stem Cells for Corneal Repair
NCT05705024Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in corneal ulcer and corneal epitheliopathy (2 arms), sponsored by University of Illinois Chicago. Primary endpoint: Improvement of Corneal Epithelial Barrier and/or Integrity at Day 28. Started Sep 2023; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
corneal ulcercorneal epitheliopathy
Beyond the preview
Go deeper on NCT05705024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705024.